Darbepoetin alfa once every 2 weeks effectively maintained hemoglobin in dialysis patients in an observational study: Austrian cohort of ALTERNATE

By Pronai Wolfgang   Neyer Ulrich   Barnas Ursula   Wieser Clemens   Jaeger Christine   Dekic Daniel   Hemetsberger Margit   Rosenkranz Alexander R.  

Wiener Medizinische Wochenschrift, Vol. 164, Iss. 5-6, 2014-03 ,pp. : 109-119

Springer Publishing Company

Access to resources Recommend Favorite

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia**

By Hernandez Enrique   Ganly Peter   Charu Veena   DiBenedetto Joseph   Tomita Dianne   Lillie Tom   Taylor Kerry    

Current Medical Research and Opinion, Vol. 25, Iss. 9, 2009-09 ,pp. : 2109-2120

Informa Healthcare

Access to resources Recommend Favorite

Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy –– data from the CHOICE study

By Van Belle S.   Karanikiotis C.   Labourey J.-L.   Galid A.   Wheeler T.   Pujol B.  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 987-994

Informa Healthcare

Access to resources Recommend Favorite

Safety and Efficacy of Trastuzumab Every 3 Weeks Combined with Cytotoxic Chemotherapy in Patients with HER2-Positive Recurrent Breast Cancer: Findings from a Case Series

By  

Oncology Research and Treatment, Vol. 28, Iss. 11, 2005-10 ,pp. : 558-564

Karger

Access to resources Recommend Favorite

Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease

By  

EUROPEAN JOURNAL OF HEART FAILURE, Vol. 17, Iss. 11, 2015-11 ,pp. : 1201-1207

John Wiley & Sons Inc

Access to resources Recommend Favorite